Amino acid supplementation decreases plasma and liver triacylglycerols in elderly

Elisabet Børsheim, Ph.D. a,*, Quynh-Uyen T. Bui, M.D. b, Sandrine Tissier, P.T. c, Melanie G. Cree, M.D., Ph.D. a, Ola Rønsen, M.D., Ph.D. a, Beatrice Morio, Ph.D. d, Arny A. Ferrando, Ph.D. a,†, Hisamine Kobayashi, D.V.M. e, Bradley R. Newcomer, Ph.D. f, and Robert R. Wolfe, Ph.D. a,†

a Department of Surgery/Shriners Hospitals for Children, University of Texas Medical Branch, Galveston, Texas, USA
b Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
c Department of Physical Therapy, University of Texas Medical Branch, Galveston, Texas, USA
d Protein and Energy Metabolism Research Unit, Human Nutrition Research Centre of Auvergne, Clermont-Ferrand, France
e AminoScience Laboratories, Ajinomoto Co., Inc., Kawasaki, Japan
f Radiography Program, University of Alabama at Birmingham, Birmingham, Alabama, USA

Manuscript received May 14, 2008; accepted September 9, 2008.

Abstract

Objective: Hypertriglyceridemia is a risk factor for coronary heart disease. The aim of this study was to determine the effect of amino acid (AA) supplementation on plasma, liver, and muscle lipid concentrations and insulin sensitivity in the elderly.

Methods: Twelve impaired glucose tolerant elderly (mean ± SD 67.0 ± 5.6 y of age, seven women and five men) ingested 11 g of essential AAs plus arginine twice a day for 16 wk, after a 7-wk control run-in. Diet and activity were not otherwise modified. Plasma lipid concentrations and oral glucose tolerance were measured every fourth week and tissue lipid concentrations (magnetic resonance spectroscopy) every eighth week.

Results: No changes in plasma lipids were observed during the control run-in. AA supplementation lowered plasma triacylglycerol (TG; \( P < 0.001 \)), total cholesterol (\( P = 0.048 \)), and very low-density lipoprotein cholesterol (\( P < 0.001 \)) concentrations. Plasma TG decreased ~20% from the initial value of 1.45 ± 0.18 mmol/L (mean ± SE, 128 ± 16 mg/dL), with the greatest decrease in the subjects starting out with the highest concentrations (\( r = -0.83 \)). Similarly, liver fat content (liver TG/Intralipid standard) decreased ~50% from the initial value of 0.34 ± 0.06 (\( P = 0.021, n = 8 \)), with the greatest decrease in the subjects who initially had the highest values (\( r = -0.86 \)). Intramuscular fat content and insulin sensitivity did not change.

Conclusion: Diet supplementation with AAs lowers plasma TG, total cholesterol, and very low-density lipoprotein cholesterol concentrations and liver lipid content in impaired glucose tolerant elderly. AA supplementation may have a potential role in the treatment of hypertriglyceridemia or hepatic steatosis. © 2009 Published by Elsevier Inc.

Keywords: Elderly; Amino acids; Plasma lipids; Liver lipids; Insulin sensitivity
Introduction

Hypertriglyceridemia has been shown to be a significant independent risk factor for coronary artery disease [1–3], and treatment for hypertriglyceridemia has been included in the Adult Treatment Panel III of the National Cholesterol Education Program [4].

Low-carbohydrate diets have been shown to positively affect plasma lipid concentrations, resulting in decreased triacylglycerol (TG) and increased high-density lipoprotein (HDL) concentrations in the presence of weight loss and compared with low-fat diets [5,6]. However, because dietary fat, carbohydrate, and protein are the primary energy-containing macronutrients, it is difficult to study the independent effects of changing one of the components of the diet [7]. If the intake of one of them is decreased, compensatory adjustments in one or both of the others must occur to maintain energy balance. Thus, most of the low-carbohydrate diets have elevated protein intake, and it is difficult to separate the independent effects of an absence of carbohydrates in the diet versus elevated protein intake. In accordance with this, studies of high-protein diets with or without weight loss also suggest a lowering effect on plasma TG concentration [8–13]. It has been difficult to separate the independent effects of protein from those of an absence of carbohydrate or change in body weight. A further complication is the type of individual macronutrient in the diet, e.g., protein of plant versus animal origin, carbohydrate with a low versus a high glycemic index, and saturated versus unsaturated fat. For example, the vegetable plant protein soy protein seems to have unique effects on plasma lipoproteins [14].

Thus, in an effort to clarify the potential independent effect of protein on plasma and tissue lipids, we supplemented a normal weight-maintaining diet with a relatively small amount of amino acids (AAs; ~90 kcal/d) between meals in the present study. We measured tissue lipids in addition to plasma lipids because the increase in insulin resistance with aging has been linked to increased fat accumulation in muscle and liver tissue [15,16]. Increased protein intake in the context of weight loss improves glucose control [17], but the effect of AA supplementation during a weight-maintaining diet is not known. Further, it has repeatedly been shown that AA intake stimulates muscle protein synthesis and improves muscle protein net balance [18]. Because muscle is the main tissue for insulin-mediated glucose uptake, it may be hypothesized that an increase in muscle mass would improve insulin action at the whole-body level.

The over-riding hypothesis of this study was that supplementation of the normal diet with a mixture of AAs would reduce circulating and tissue TG concentrations and improve insulin sensitivity in elderly subjects with impaired glucose tolerance. The aim of the study was to investigate the effect of supplementation of the diet with essential AAs (EAAs) plus arginine on plasma, liver and muscle lipids, and insulin sensitivity in impaired glucose tolerant elderly subjects.

Materials and methods

Study design

Twelve elderly volunteers participated in an approximately 24-wk study period. After a run-in period of observation of ~7 wk, they ingested 11 g of EAAs plus arginine two times a day, between meals, for 16 wk. Diet and activity were not otherwise modified. Every fourth week after the start of AA ingestion, the subjects were admitted to the General Clinical Research Center (GCRC) at University of Texas Medical Branch (UTMB), Galveston. Body composition was measured by an oral glucose tolerance test (OGTT). In addition, a plasma lipid panel was determined. Muscle and liver lipids were measured by magnetic resonance spectroscopy every eighth week. At weeks 0 and 16, a muscle biopsy was also collected from the musculus vastus lateralis for measurement of activities of oxidative enzymes. The protocol was approved by the institutional review board at UTMB and the GCRC advisory committee at UTMB.

Subjects

Twelve impaired glucose tolerant elderly subjects (seven women and five men, mean ± SD 67.0 ± 5.6 y of age, 164.5 ± 16.4 cm, 74.3 ± 19.7 kg at baseline) participated in the study. They were fully informed about the purpose and procedures of the study before written consent was obtained. Each subject had a complete medical screening at the GCRC before participation in the experiments (51 ± 9 d before the start of supplementation), including vital signs, blood tests, urine tests, and a 12-lead electrocardiogram, and these results were used as a baseline for the placebo run-in period for those subjects who qualified to participate in the study. Exclusion criteria included evidence of heart disease, hyperlipidemia, kidney or liver disease, or any other disease that might influence the results of the study. Hyperlipidemia was excluded because we wanted to examine the effect of protein in the elderly without the confounding variable of pre-existing hyperlipidemia. The subjects also underwent a standard OGTT using 75 g of glucose. Only subjects with impaired glucose tolerance, defined as a plasma glucose concentration >10 mmol/L (180 mg/dL) at 1 h or >7.8 mmol/L (140 mg/dL) at 2 h after an oral intake of 75 g of glucose, were included. Diabetic subjects (plasma glucose concentration >11.1 mmol/L [200 mg/dL] at 1 or 2 h after glucose intake) with a decreased insulin production and subjects taking any medication to treat abnormal blood lipid levels were not included in the study.
Nutritional supplement

Each dose of the nutritional supplement consisted of 11 g of AAs with the following composition: 0.36 g of histidine, 0.94 g of isoleucine, 3.95 g of leucine, 1.88 g of lysine · HCl, 0.39 g of methionine, 0.51 g of phenylalanine, 1.05 g of threonine, 0.82 g of valine, and 1.10 g of arginine. The choice of AAs was based on our numerous previous findings in muscle that only EAs are needed for stimulation of protein synthesis [19,20]. Thus, we expected that only the EAAs were needed to achieve an effect, and the amount given (grams or kilocalories) could be restricted. We included arginine in addition to the EAAs because arginine may have unique anabolic effects [21,22]. The supplement was taken in two daily doses in the form of capsules and recorded in a diary. The first dose was taken between breakfast and lunch, and the second dose was ingested between lunch and dinner. The subjects visited the hospital every 2 wk to pick up a new supply of supplements. In the weeks with no hospital visits, the subjects were given follow-up calls to check on the intake of the supplements and on the diet, activity, and anything else (sickness, etc.) that might influence the results of the study.

Diet and physical activity

Before the start of the study the subjects were counseled to maintain their typical dietary intake and physical activity pattern. During their visits to the hospital and in telephone calls between visits, they were asked about this and reminded to not make any changes. The Physical Activity Scale for Elderly was used to measure their physical activity during the study period. Further, at the start of the study the subjects were instructed by the dietitian at the GCRC on how to complete a diet diary. In the week before the first overnight stay and every fourth week thereafter (weeks 3, 7, 11, and 15), the participants recorded their diet for 3 d overnight stay and every fourth week thereafter (weeks 3, 7, 11, and 15), the participants recorded their diet for 3 d.

Magnetic resonance spectroscopy

Every eighth week, the intramuscular lipid concentration of the musculus soleus was measured with a 1H knee coil on a GE Advantage 1.5-T whole-body imager (General Electric, Milwaukee, WI, USA), as previously described [16]. The widest part of the calf was located during the first study and measured from the floor and marked. A marker was placed at the location during the scan, and this slice of leg was always used for scans. Four areas were selected from the coronal slice localizer and traced onto a transparency along with multiple anatomic landmarks. These four areas were then rescanned during each subsequent magnetic resonance spectroscopic analysis. A tube of 20% Intralipid (intravenous high-fat total parenteral feeding solution; Baxter Healthcare, Deerfield Park, IL, USA) was placed inside the knee coil to obtain a standard external reference [23]. After a preliminary localization image, three to seven voxels (∼7 mm × 7 mm × 10 mm each) were chosen in the musculus soleus free from fascia, gross fat marbling, and vessels. The exact voxel volumes were recorded. A voxel was also chosen from the Intralipid external reference. An optimized point resolved spectroscopic sequence with a repetition time of 2000 ms and an echo time of 35 ms was run. Peak positions and areas of interest (extramuscular [CH2]n, intramuscular [CH2]n, extramuscular CH3, intramuscular CH3, total creatine, and trimethylamine) were determined by time domain fitting using jMRUI [24,25]. In brief, all water-suppressed free induction decay (FID; metabolite FID) were deconvoluted with the water-unsuppressed FID (water FID) acquired from the same voxel to correct for zero-order phasing and removal of eddy current-induced artifacts [26]. The resulting metabolite FIDs were analyzed with AMARES (Method of Accurate, Robust and Efficient Spectral fitting), a non-linear least-square-fitting algorithm operating in the time domain [16,27,28]. Spectra from voxels, which did not have optimal shimming or clear intracellular and extracellular lipid peak resolution, were not used in the AMARES fitting analysis. This process was repeated for the Intralipid phantom. The TG levels were computed as a ratio relative to the Intralipid standard using the following formula: TG = (PM/VM)/(PI/VI), where PM is the methylene peak area, VM is the total measured tissue voxel volume, PI is the Intralipid peak area, and VI is the Intralipid voxel volume. This measurement is a TG concentration normalized to Intralipid concentration, and thus it is unitless.

Liver lipid concentration was measured with a 1H whole-body coil on the same system. Hepatic measurements were performed in the middle right lobe [29]. The scans were localized to the same area of the liver by anatomic landmarking of the hepatic blood flow and the ribs, so that approximately the same area of liver was scanned with each study. A tube of Intralipid was used for reference. After a preliminary localization scan, a voxel (∼30 mm × 30 mm × 20 mm) was chosen at a location free from large vessels. An optimized point resolved spectroscopic sequence was run 256 times without respiratory gating. These spectra represent an average lipid concentration measurement over the midnight lobe. Spectra were manually phased, and final analysis was then performed with jMRUI.

Dual-energy x-ray absorptiometry

The subjects underwent a full-body dual-energy x-ray absorptiometric scan every fourth week to determine body composition. All dual-energy x-ray absorptiometric scans were performed on a Hologic QDR 4500 A system (Hologic, Inc., Bedford, MA, USA).
Oral glucose tolerance test

An OGTT was performed every fourth week to determine insulin sensitivity. The subjects were fasted for about 12 h before the OGTT. A catheter was placed in a vein in the arm, and two background blood samples were drawn. Thereafter, the subjects received 75 g of glucose (Glucola, Fisherbrand LIMEONDEX, Fisher HealthCare, Houston, TX, USA). Blood samples were collected at 30, 60, 90, and 120 min after the glucose ingestion for the determination of plasma glucose, insulin, and glycerol concentrations. The first blood sample was also analyzed for plasma lipid panel and, in weeks 0 and 16, AA concentrations.

Muscle biopsy

In weeks 0 and 16, a muscle biopsy was taken after the OGTT, under local anesthesia, from the lateral portion of the vastus lateralis, approximately 10–15 cm above the knee. A 5-mm Bergstrom biopsy needle (Depuy, Warsaw, IN, USA) was used to sample approximately 30–50 mg of mixed muscle tissue. The sample was quickly rinsed, blotted, and immediately frozen in liquid nitrogen and stored at −80°C for later analysis of citrate synthase, cytochrome c oxidase, and β-hydroxyacyl-coenzyme A dehydrogenase (β-HAD) activities.

Sample analyses

Plasma glucose concentration was determined enzymatically (YSI 1500, Yellowspring Instruments, Yellowspring, OH, USA). Plasma insulin concentration was determined by a radioimmunoassay method (Diagnostic Products Corporation, Los Angeles, CA, USA). Plasma AA concentrations were analyzed by high-performance liquid chromatography (Waters Alliance HPLC System 2690, Milford, MA, USA). Enzymatic methods were used to determine plasma free fatty acids (FFAs; NEFA-C, Wako Chemicals GmbH, Neuss, Germany) and glycerol (Sigma-Aldrich, St. Louis, MO, USA) concentrations. The lipid panel was comprised of TGs, total cholesterol, and HDL cholesterol concentrations. These were measured on a Vitros 950 system (Ortho-Clinical Diagnostics, Raritan, NJ, USA). The HDL cholesterol was measured by precipitation of low-density lipoprotein (LDL) and very LDL (VLDL), and the cholesterol left in the supernatant (HDL) was then determined. The LDL cholesterol (milligrams per deciliter) was calculated using Friedewald’s equation (LDL cholesterol = total cholesterol − HDL cholesterol − [TG/5]) [30]. Thus, the quotient TG/S is used as an estimate of VLDL cholesterol concentration. The cholesterol concentrations (milligrams per deciliter) were then multiplied by 0.02586 for conversion to the International System of Units (millimoles per liter). Similarly, TG concentrations were multiplied by 0.01129 for conversion.

Mitochondrial enzyme activities of citrate synthase, cytochrome c oxidase, and β-HAD were measured from homogenates of musculus vastus lateralis biopsies in a sucrose/ethylene-diaminetetra-acetic acid/Tris buffer, as previously described [31].

Calculations

Whole-body insulin sensitivity after a 75-g glucose load was estimated by the composite model for insulin sensitivity designed by Matsuda and DeFronzo [32] as the Insulin Sensitivity Index (ISI) = 10 000/([fasting glucose × fasting insulin] × [mean glucose × mean insulin during OGTT])½. The value derived from this equation is an M value of glucose uptake in milligrams per square meter per minute, which is approximated to the results that would likely have been obtained if a more invasive hyperinsulinemic-euglycemic clamp test had been performed. The range of values is 0–14, with insulin sensitivity being better with a higher ISI. The area under the curve for plasma glucose and insulin concentrations was also determined, with the average pre-OGTT concentration used as the zero point.

Statistical methods

Overall significance of differences in response of diet intake, ISI, tissue lipids, and fasting plasma lipids, insulin, and glucose concentrations with time was tested by one-way repeated measures analysis of variance followed by Dunnett’s test with week 0 as a control (SigmaStat 2.03, SPSS Inc., Chicago, IL, USA). The correlation between plasma TG concentrations at week 0 and changes in plasma TG concentration during the supplementation period was measured by Spearman’s rank correlation coefficient, whereas the corresponding correlation for liver lipid content was determined by linear regression analysis. Significance of changes in the time course of glycerol, insulin, and glucose concentrations during the OGTT was tested by two-way repeated measures analysis of variance, with week 0 and pre-OGTT values as controls. Changes in AA concentration or muscle oxidative enzymes from week 0 to 16 were tested by paired t tests. Comparisons of plasma lipid concentrations and ISI at screening (week −7) and week 0 were also done by paired t tests. Results were considered statistically significant if \( P < 0.05 \). The results are presented as mean ± SE unless otherwise noted.

Results

The AA supplementation was well tolerated by the subjects, and there were no overall changes in physical activity or diet during the study period. The dietary intake was 1733 ± 226 kcal/d when no supplement was taken versus an average of 1735 ± 176 kcal/d during the supplementation period (\( n = 9 \)). Corresponding values for protein intake were 1.03 ± 0.19 versus 0.99 ± 0.21 g · kg\(^{-1} \) · d\(^{-1} \), fat intake was 0.86 ± 0.15 versus 0.86 ± 0.09 g · kg\(^{-1} \) · d\(^{-1} \),
and carbohydrate intake was 3.05 ± 0.70 versus 3.11 ± 0.70 g · kg⁻¹ · d⁻¹.

The AA supplementation did not lead to changes in overall body mass (week 0 versus 16: 74.31 ± 5.67 versus 74.60 ± 5.62 kg), body mass index (27.9 ± 1.8 versus 28.0 ± 1.9 kg/m²), total fat mass (24.19 ± 3.59 versus 23.90 ± 3.70 kg), or trunk fat mass (11.89 ± 1.76 versus 11.67 ± 1.78). Fasting plasma AA concentration did not change during the study.

**Plasma lipids**

There were no changes in plasma TG, total cholesterol, LDL, HDL, or VLDL cholesterol concentrations during the run-in period from the time of screening until the start of the supplementation period (51 ± 9 d without supplementation; Table 1).

Significant decreases were found in plasma TG (P < 0.001), total cholesterol (P = 0.048), and VLDL cholesterol (P < 0.001) concentrations during the AA supplementation (Table 1). For TG and VLDL cholesterol the changes from baseline were significant at all time points, whereas they did not reach significance at any specific time point for total cholesterol concentration.

The changes in plasma TG concentrations during the study were related to starting level, with the greatest decrease in the subjects who initially had the highest plasma TG concentrations (Fig. 1). The correlation was not linear; therefore, we calculated Spearman’s rank correlation coefficient, which was r = −0.828 between the starting value and the average change from baseline at 4, 8, 12, and 16 wk (P < 0.001). Most of the concentration changes occurred somewhere between 0 and 4 wk (Table 1). Spearman’s rank correlation coefficient between the start value and the change from 0–4 weeks was −0.872 (P < 0.001).

No changes were found in plasma FFA and LDL and HDL cholesterol concentrations during the study (Table 1).

**Liver and muscle lipids**

At the start of the study, there was a linear correlation between liver fat content and plasma TG concentration (r = 0.85, P = 0.007). AA supplementation caused the liver fat content (liver TG/Intralipid standard) to decrease about 50% from the initial value of 0.34 ± 0.06 at week 0 (P = 0.021, n = 8 at weeks 0 and 16, n = 6 at week 8; Fig. 2). The change in liver fat content was most dramatic for the subjects starting out with the highest level (r = −0.86, P = 0.006). No significant changes were observed in intramuscular fat content.

**Muscle oxidative enzymes**

No significant changes were found in the mitochondrial enzyme activities of citrate synthase (week 0 versus...
Hepatic fat content may increase three- to four-fold within 1 wk of the initial injury [33]. The values of liver TG in the present study were as expected based on our previous measurements in insulin-resistant elderly and higher than values in elderly with normal glucose tolerance [34]. However, in our previous work we found a correlation between the extent of insulin resistance and the amount of liver TG [16], whereas in the present study a decrease of liver fat failed to affect insulin sensitivity. It appears that liver TG is not the sole determinant of insulin sensitivity in elderly individuals.

The mechanisms underlying the effect of AA supplementation on liver and plasma lipid concentrations are not known. The amount of liver lipids can be influenced by the rate of uptake (and hence delivery) of plasma fatty acids, the rate of hepatic fatty acid oxidation, and the rate of secretion of TG in VLDL. Because there was no change in plasma FFA concentration and no detectable change in whole-body or trunk fat mass, it seems unlikely that changes in rate of lipolysis and thus delivery of fatty acids to the liver can explain the 50% reduction in liver lipids. It is possible that a greater percentage of FFAs taken up in the liver was oxidized, but because most energy in the liver is normally derived from fat oxidation [35], it is unclear if EAAs could further stimulate fat oxidation sufficiently to reduce the intracellular stores of TG. Thus, the most likely explanation for the decrease in hepatic TG is an accelerated secretion in the form of VLDL-TG, possibly by EAA stimulating synthesis of VLDL apoproteins.

An increased efficiency in TG secretion from the liver implies that peripheral clearance of TG was increased, because the plasma TG level decreased significantly. It is further possible that, if clearance were accelerated, the reduction in plasma TG concentration would in turn be a stimulus for a greater rate of secretion of TG from the liver (thereby explaining the reduction in hepatic TG). We found no effect of EAAs on muscle tissue citrate synthase, cytochrome c oxidase, and β-HAD, suggesting that mitochondrial number or oxidative capacity remained unchanged. It therefore seems unlikely that increased oxidation of fatty acids in the muscle could explain enhanced peripheral TG clearance. Further, there was no change in the size of the intramuscular TG pool. Rather than muscle, adipose tissue may be the principal site of increased TG clearance. Under normal conditions about 70% of fatty acids released from adipose tissue as FFAs are incorporated into TG in the liver and transported back to the adipose tissue in the form of TG [36]. At the adipose tissue the fatty acids from the circulating TG are reincorporated into TG for storage. This pathway has been termed the “extracellular” pathway of TG-fatty acid substrate cycling [37]. A stimulation of lipoprotein lipase activity at the adipose tissue level would explain a stimulation of TG clearance by EAA intake by the “extracellular” route of substrate cycling. Further studies will be required to determine if such a stimulation occurs.

A decrease in plasma TG concentrations has been observed in relation to high-protein/low-carbohydrate diets.

16: 0.22 ± 0.02 versus 0.24 ± 0.03 μmol · min⁻¹ · mg⁻¹), cytochrome c oxidase (0.20 ± 0.02 versus 0.19 ± 0.03 μmol · min⁻¹ · mg⁻¹), or β-HAD (130.3 ± 9.8 versus 123.8 ± 12.3 μmol · min⁻¹ · mg⁻¹).

**Oral glucose tolerance test**

No significant effect of AA supplementation on the ISI (Matsuda score) was found (Table 1). Further, no correlations were found between starting values and changes in ISI or between changes in ISI and lean body mass or leg lean mass, respectively.

In agreement with the ISI, no overall changes in the area under the curve of glucose or insulin were found during the study. Further, whereas the glycerol concentration during the OGTT decreased (P < 0.05 versus baseline), there was no interaction effect between week of supplementation and time course of glycerol during the OGTT.

**Discussion**

The main finding in this study was that supplementation of a normal weight-maintaining diet with EAAs plus arginine decreased plasma and liver TG content and also total cholesterol and VLDL cholesterol concentrations in the elderly. Further, the decreases in plasma and liver TG concentrations were related to the starting level, suggesting a potential role for AAs in the treatment of hypertriglyceridemia. Insulin sensitivity was not significantly improved as a result of AA supplementation.

The magnitude of change in liver lipid concentration was large (~50%), and the response was rapid. The maximal decrease was achieved by 8 wk. The rapid response of liver lipids is consistent with previous work, as in burn patients hepatic fat content may increase three- to four-fold within 1 week.
but the independent effects of a low carbohydrate intake, increased protein intake, and changes in body weight are unclear. In a crossover feeding study, it was found that, in the setting of a healthy diet low in saturated fat, a diet rich in protein (approximately half from plant sources) significantly lowered plasma TG levels compared with a carbohydrate-rich diet [13]. Because the effect was also significantly greater than what was seen after a diet rich in unsaturated fat, the investigators suggested that protein may have a direct TG-lowering effect beyond that of replacing carbohydrates, which is known to increase TG levels. To our knowledge there are no previous studies of the effect of AAs on plasma and tissue lipids, except that AA solutions have been given to patients on dialysis. Thus, patients on peritoneal dialysis receiving 1.1% solution of AAs instead of all glucose demonstrated a 13% decrease in plasma TG concentration within 1 mo of the solution change [38]. In a longer study using AA dialysate for 3 y, patients showed a significant decrease in plasma TG concentration [39]. The present study shows that the TG-lowering effect can be achieved by supplementing the normal diet with a small amount (expressed as grams or kilocalories) of AAs. Further, an intriguing finding is that the effect was greater at higher TG levels. The use of AA supplementation as treatment for patients with hypertriglyceridemia or hepatic steatosis merits further studies.

Insulin action declines with age [40]. This has been linked to increased fat accumulation in muscle and liver tissue [15,16]. However, the decrease of liver and plasma lipids in the present study did not translate to an improvement in insulin sensitivity. This implies that muscle fat accumulation (or muscle lipid metabolism) may be more important for insulin resistance than liver fat accumulation. This may be expected because muscle is the primary site of insulin-stimulated glucose disposal.

We assumed that no improvement in plasma or tissue lipids would occur over 16 wk without intervention. This assumption is supported by the stability of the lipid values over the 7-wk run-in period preceding the study (Table 1). Further, the subjects had no conscious control over the measured endpoints, except that modifying activity or food intake could have potentially influenced the results. We did not find any changes in activity or food intake during the supplementation period, and the measurements of lipid parameters were made under the same standardized conditions each time. Consequently, we feel confident that the changes observed in this study were due to the ingestion of the AAs.

The potential detrimental effects of high levels of protein intake have been dealt with extensively in the dietary reference intakes report of the Food and Nutrition Board [41]. The report concluded that there is no documented adverse effects of high-protein intake and consequently set no upper limit on safe protein intake. There are no such data regarding ingestion of AA formulations, but one would expect a similar lack of detrimental effects.

**Conclusion**

Supplementation of a normal weight-maintaining diet with EAs plus arginine decreases liver and plasma TG concentrations in impaired glucose tolerant elderly. The effect is related to the starting level of plasma TG; thus, AA supplementation may have a potential role in the treatment of hypertriglyceridemia or hepatic steatosis. Because insulin sensitivity was not improved despite the reduction in liver fat content, the storage of fat in the liver is not the primary determinant of insulin sensitivity. Plasma total cholesterol and VLDL cholesterol are also decreased by the AA supplementation.

**Acknowledgments**

The authors thank the subjects who participated in the study for their time and dedication. They thank Sue Minello, R.N., Roxana Hirst, M.S., and Nancy Poore at the Pepper Center for help in recruiting the volunteers, and the nurses, dietitians, and staff at the General Clinical Research Center at the University of Texas Medical Branch at Galveston. They thank Kendrick Armstrong, Melissa Bailey, Donovan Randolph, Stephaine J. Blase, Tara Cocke, Daniel L.Creason, Christopher P. Danesi, Scott Schutzler, and Paulette Rousset for skillful technical assistance. They acknowledge Elizabeth Protas, Ph.D., for support of Sandrine Tissier.

**References**

288


